Thyrogen (Thyrotropin Alfa)
Customize your policy alerts
Sign up for Aetna Policy 0515 alerts
Get alerted when Policy 0515 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage policy for Thyrogen (thyrotropin alfa) for commercial medical plans, detailing indications, dosing, experimental uses, and applicable coding; affects providers ordering/administering Thyrogen for patients with differentiated thyroid carcinoma and nontoxic multinodular goiter.
No material clinical or coverage changes in this revision.
Coverage Criteria for Thyrogen (thyrotropin alfa)
Evidence summaries
Evidence summaries — key trials, meta-analyses, and outcomes relevant to Thyrogen (thyrotropin alfa).
ALL of the following
- Randomized trials comparing rhTSH (Thyrogen) preparation versus thyroid hormone withdrawal (THW) for radioiodine remnant ablation (RRA) show comparable ablation success rates at 6–12 months. Pacini et al (2006) reported similar remnant ablation (96% rhTSH vs 86% THW; p=0.23) and improved quality of life and lower blood radiation exposure with rhTSH.
Source: chunk11
- A 2014 systematic review and meta-analysis (Pak et al) of 6 randomized trials (1,660 patients) found no significant differences in ablation success between rhTSH and THW across multiple definitions of success (Tg cut-offs of 1 or 2 ng/mL and imaging-based definitions).
Source: chunk18
- For facilitation of RAI ablation after surgery, randomized data support that rhTSH is an effective alternative to thyroid hormone withdrawal, with comparable ablation outcomes and improved patient-reported quality of life during preparation.
Sources: chunk11, chunk18
- rhTSH as an adjunct to radioiodine therapy for benign non-toxic multinodular goiter: Two randomized, double-blind placebo-controlled trials (Fast et al, pooled n=86) with long-term follow-up (median ~71 months) demonstrated greater goiter volume reduction and improved goiter-related symptoms with rhTSH-augmented (131)I therapy versus (131)I alone, but with higher rates of hypothyroidism in the rhTSH group. Additional therapy was required less often in the rhTSH group (2/42 vs 9/44).
Source: chunk15
- Safety and long-term outcomes: A 2023 meta-analysis (Sunavala-Dossabhoy & Petti) examining long-term salivary gland dysfunction (LT-SGD) after RAI found pooled relative risks suggesting reduced LT-SGD with rhTSH preparation versus THW (fixed-effect RR 0.65; random-effects RR 0.62, with some models crossing unity). Stratified results suggested protection at higher RAI activities (>=3.7 GBq RR 0.75; 95% CI 0.57–0.98). The authors judged evidence moderate quality that rhTSH may protect salivary gland function.
Sources: chunk21, chunk22
- In patients with suppressed Tg (<0.1 ng/mL on T4 suppression), rhTSH-stimulated thyroglobulin testing has limited additional utility: Chindris et al (2012) found most such patients remain undetectable or minimally increased after stimulation and that periodic suppressed Tg and neck ultrasound adequately detected recurrences; rhTSH testing did not change management in this group.
Source: chunk17
- Evidence on benign thyroid nodules: Small study data (Bountouris et al, 2023) indicate transient increases in nodule and thyroid parenchyma volume 48 hours after a low 0.3 mg dose of rhTSH, with volumes returning to baseline by 6 months; responses were heterogeneous. Clinical benefit for benign nodules remains uncertain.
Source: chunk19
Coding and Diagnosis Codes
| 78012 | Thyroid uptake, single or multiple quantitative measurement(s) (including stimulation, suppression, or discharge, when performed). |
| 78013 | Thyroid imaging (including vascular flow, when performed). |
| 78014 | with single or multiple uptake(s) quantitative measurement(s) (including stimulation, suppression, or discharge, when performed). |
| 78015-78018 | Thyroid carcinoma metastases imaging. |
| 78020 | Thyroid carcinoma metastases uptake (List separately in addition to code for primary procedure). |
| 80418 | Combined rapid anterior pituitary evaluation panel. |
| 80438 | Thyrotropin releasing hormone (TRH) stimulation panel; one hour. |
| 80439 | TRH stimulation panel; two hour. |
| 84432 | Thyroglobulin. |
| 84443 | Thyroid stimulating hormone (TSH). |
| C73 | Malignant neoplasm of thyroid gland [except for suppressed serum thyroglobulin (less than 0.1 ng/ml)]. |
| E04.2 | Nontoxic multinodular goiter [adjunct to radioiodine ablation]. |
| Z85.850 | Personal history of malignant neoplasm of thyroid. |
Provider Actions, Authorization, and Documentation
Prior Authorization Required
Prior authorization required for Thyrogen (J3240) when used for thyroglobulin (Tg) testing and radioiodine imaging in place of thyroid hormone withdrawal — ensure authorization is obtained before administration.
- Affected code: J3240 (Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial)
- Indications requiring prior auth: Tg testing and radioiodine imaging as an alternative to thyroid hormone withdrawal for differentiated thyroid carcinoma; facilitation of radioiodine ablation after surgery; adjunct to radioiodine ablation for non-toxic multinodular goiter.
Step Therapy / Standard Alternative
Step therapy: thyroid hormone withdrawal (THW) remains the standard diagnostic modality and is the preferred/standard alternative. Use of Thyrogen (thyrotropin alfa) is appropriate when THW is contraindicated, not acceptable to the member, or the member is unable to mount an adequate endogenous TSH response. Document clinical rationale for using Thyrogen instead of THW.
- Standard alternative: thyroid hormone withdrawal (THW)
- When Thyrogen may be used instead: contraindication to THW, patient unwilling to undergo THW and physician justification, inadequate endogenous TSH response, or to avoid sole reliance on Tg testing without withdrawal.
No Explicit Step Therapy Requirements
No additional step therapy requirements are specified beyond the preference for thyroid hormone withdrawal as the standard diagnostic approach. There are no described mandated trial durations or fail-first numeric thresholds in the provided policy text.
- Policy does not list mandatory step-fail timeframes or numeric thresholds prior to Thyrogen use.
Required Clinical Documentation
Required clinical documentation should include diagnosis codes supporting the indication (e.g., C73, E04.2, Z85.850), clinical rationale for using Thyrogen instead of thyroid hormone withdrawal (contraindication, patient refusal, inadequate TSH response, undetectable Tg on suppressive therapy), and relevant test results (serum Tg, TSH levels, anti-Tg antibody status) and treatment history (thyroidectomy, prior radioiodine ablation). Include dosing plan (two 0.9 mg IM injections 24 hours apart) and ordering/provider information.
- Suggested ICD-10 codes: C73 (malignant neoplasm of thyroid), E04.2 (nontoxic multinodular goiter), Z85.850 (personal history of malignant neoplasm of thyroid)
- Document: clinical justification for avoiding THW, serum Tg and TSH results, anti-Tg antibody status, prior treatments, and planned Thyrogen dosing regimen.
Experimental/Investigational — Denial Risk
Use of thyrotropin alfa for indications not listed as medically necessary (for example, in individuals with suppressed serum thyroglobulin <0.1 ng/mL or other unapproved uses) is considered experimental/investigational and may lead to denial of coverage.
- Experimental/Investigational — denial risk: any indication outside the approved/medically necessary uses described in the policy (e.g., suppressed serum Tg <0.1 ng/mL).
Background and Scope
Thyrogen (recombinant human thyroid‑stimulating hormone, rhTSH) is FDA‑approved as an adjunctive diagnostic agent to facilitate serum thyroglobulin testing with or without radioiodine imaging in the follow‑up of well‑differentiated thyroid cancer, and as an adjunct to radioiodine remnant ablation after thyroidectomy. It stimulates thyroglobulin production and radioiodine uptake so that testing or ablation can often be performed without thyroid hormone withdrawal, thereby avoiding the hypothyroid period associated with withdrawal. Limitations noted in the policy include lower sensitivity compared with withdrawal in some settings and potential assay confounding by anti‑thyroglobulin antibodies; clinical use should follow the policy’s covered indications and documentation requirements.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.